ALXN News and Press, Alexion Pharmaceuticals Inc. From 12/28/20

Aravive is drugging the GAS6-AXL pathway to develop new medicines across several cancer indications. Early clinical data has established safety for the company's lead drug candidate, AVB-500, and early efficacy signals in platinum-resistance ovarian cancer. AVB-500 has the potenti...

NEW YORK, NY / ACCESSWIRE / December 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: American Renal Associates Holdings, Inc. (NYSE: ...

Novavax's COVID-19 vaccine has shown efficacy in clinical trials. Late-stage trials could commence within days. NVAX's vaccine can be stored at refrigerated temperatures. Mass doses could potentially be easier to distribute vis-a-vis PFE or MRNA. The stock trades at 2x projected 2...

Do You Have These Top Biotech Stocks On Your End Of Year Watchlist? Biotech stocks are at the center of attention this year in the stock market and will likely still be in 2021. This is because many of these biotech companies were trying to develop vaccines and treatments fo...

The recent acquisition of rare dug heavyweight Alexion Pharmaceuticals signals a willingness of big pharma to enter the field. Typically, big pharma was interested in larger patient populations however the lack of commercial ready products has broaden their focus. With interest ra...

Earlier this month, AstraZeneca (NASDAQ: AZN) announced plans to acquire rare-disease expert Alexion (NASDAQ: ALXN) for $39 billion. In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contribut...

NEW YORK, NY / ACCESSWIRE / December 19, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) concerning potential violations of the federal securities laws and/or breaches of f...

Remove your emotions by following rules-based investing. Stick to what works. Big market corrections may provide you with these long-awaited opportunities for your greatest profits. For further details see: Had I Listened To My Own Advice

22nd Century Group (XXII) has been on an incredible run since receiving a new U.S. patent for breakthrough technology that helps reduce nicotine in tobacco plants. Read ahead to find out if XXII can continue its momentum. The company is awaiting imminent authorization of its MRTP (Modified Ri...

Big cash flows from a handful of successful new cancer drugs recently emboldened AstraZeneca (NASDAQ: AZN) to make a huge bet on Alexion Pharmaceuticals (NASDAQ: ALXN) and its successful drugs for rare diseases. AstraZeneca offered $39 billion for Alexion in a combi...